US abortion row rekindled by move on British pill
Monday 21 February 1994
News that the Marie Stopes clinic in London has been authorised by the Department of Health to offer the drug to American women has rekindled a long-running controversy over the use of RU-486 here. Anti-abortion groups are campaigning to keep the pill off the US market; the pro-choice camp says women have a moral right to use it.
Renewed interest in the pill coincides with other developments helping to re-ignite the already passionate abortion debate in America. Today jury selection starts in the trial in Pensacola, Florida, of Michael Griffith, who is charged with murdering an abortion doctor, David Gunn, last March.
Last month, meanwhile, the US Supreme Court issued a landmark ruling that groups anti-abortion activists who take physical action to disrupt abortion clinics or intimidate women seeking to terminate pregnancies with all other political terrorists and criminal extremists. The penalties for such action are consequently likely to become much more severe.
Pamela Maraldo, the president of the pro-choice Planned Parenthood organisation, speaking of the decision on RU-486, declared: 'We're ecstatic. It's delightful that RU-486 is going to be available in Britain, but it's still unacceptable that something so safe and effective would require a trip across the Atlantic.'
Anyone hoping to attend the Stopes clinic from here will have to make a considerable investment of time and money. Apart from the plane ticket, they will have to pay roughly dollars 500 ( pounds 340) for the treatment, which will require the patient to spend one night in the clinic and to remain in London for almost two weeks for observation. 'It doesn't do much good to poor women to know it's available in London,' Ms Maraldo conceded.
The pill, which is marketed in Britain under the name Mifegyne, is made by the French Roussel- Uclaf company. Since its introduction in France six years ago it has become a popular alternative to surgical abortions. The only other countries where it has so far been approved are Britain and Sweden.
The Clinton administration has indicated it would favour approval of the drug in the US. Roussel-Uclaf and the non-profit Population Council in New York have been trying to find a US company that could make the pill under licence and market it in this country. Roussel-Uclaf's parent, Hoechst of Germany, is said to be nervous about the reaction of anti-abortion forces if a deal is reached, and the possibility of a boycott of all its products.
Groups against abortion rights have lobbied doctors and law-makers with a postcard campaign to resist the introduction of RU-486 in the US.
- 1 Game of Thrones season 6: Jon Snow theorists believe Ned Stark's son may have a twin sister
- 2 Artist takes LSD, draws herself over different stages of the 9-hour trip to show its effects
- 4 iPhone 6s camera: features to include 4K video camera and flash for selfies
- 5 A pint of water every day is the key to losing weight, scientists say
Miley Cyrus address Robin Thicke VMA controversy: ‘He wanted me as naked as possible, but I got the heat because I’m a woman’
Most expensive city to live in for expatriates: Luanda, Angola takes number one spot with Hong Kong and Zurich in top three
If Surrey were Syria: Social experiment shows what it's like to live under siege
Irish tourist filmed fighting with shopkeepers in Turkey says they 'messed with the wrong man'
House of Lords: Outcry as donors, fixers and MPs caught up in expenses scandal get peerages
Dresden riots: Protesters in Germany attack refugee buses shouting 'foreigners out'
France train shooting: US soldiers speak of the moment they stopped gunman and 'beat him until he was unconscious'
Labour leadership: Jeremy Corbyn accused of 'deluding' young supporters with 'claptrap'
'Women only' train carriages: Jeremy Corbyn unveils radical move to tackle public harassment
Black holes are a passage to another universe, says Stephen Hawking
Iain Duncan Smith 'should resign over disability benefit death figures', says Jeremy Corbyn
£26000 - £29000 per annum: Recruitment Genius: The Product Development departm...
£19000 per annum: Recruitment Genius: This hull based charity providing except...
£9464 - £10396 per annum: Recruitment Genius: The successful applicant will ne...
£32000 - £40000 per annum: Recruitment Genius: With extensive experience and a...